Marketresearchnews

Tuesday, 15 June 2021

MEA Urinary Tract Infection (UTI) Drugs Market Growth, Trends and Value Chain 2020-2027

Urinary tract infection (UTI) is the infection of the lower or upper urinary tract generally due to escherichia coli although other bacteria and fundi may be causative organisms. Symptoms include pain with urination, frequent urination and feeling the need to urinate despite having an empty bladder. Risk factors that may cause UTI include female anatomy, sexual intercourse, diabetes, obesityetc. World Health Organization (WHO) estimates that approximately 50 % of women suffer from UTI at some point of time in their lives resulting in more than 1 million hospitalizations per year. WHO estimates the annual cost of UTI infections treatment to be greater than $1 billion. It has further been stated that 1% of boys and 3-8% of girls are diagnosed with UTI. .

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2540

The Middle East and African urinary tract infection (UTI) drugs market is growing due to factors such as catheter associated UTI, hospital borne infections (nosocomial infections), child birth, old age, obesity, growing health awareness especially about women health etc. However, there remain market constraints such as drug resistance, unmet clinical needs, increasing incidence of chronic diseases etc. Another prominent restrain is the excellent efficacy of present antibiotics specially the quinolones. However the rise of drug resistance has negated this constraint and had opened doors to new drug development as a good strategy for UTI treatment.

Taking all these factors into consideration, the Middle East and Africa UTI drugs market had reached around $ 992.84 million from $ 769 million in 2015 by growing at the CAGR of 4.35%.

Study Objectives Middle East and Africa UTI Drugs Market:

To provide detail analysis of the MEA Urinary Tract Infection (UTI) Drugs Market Trends along with forecast for the next 5 years about various segments and sub segments of the Middle East and African UTI Drugs market.
To provide insights about factors affecting the market growth.
To analyze the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.
To provide past and estimated future revenue of Middle East and Africa UTI drugs market’s segments and sub-segments.
To provide country level analysis of the market with respect to the current market size and future growth prospect.
To provide country level analysis of the market’s segments which includes by drug class, by clinical indication, by end users and other sub segments.
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies and drawing a competitive landscape of the market
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments taking place globally.

Intended Audience

UTI drugs manufacturers
UTI drugs suppliers
Private research laboratories
Research and development (R&D) companies
Market research and consulting service providers
Government research laboratories
Contract manufacturing organizations

Key Players of Middle East and Africa UTI Drugs Market:

Some of the key players in this market are: Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Dr. Reddy’s Laboratories Ltd. and others.

Segments:

Middle East and Africa UTI drugs market has been segmented on the basis of drug class which comprises of quinolones, aminoglycosides, β-lactam, azoles and others. On the basis of clinical indications this market is segmented into urethritis, cystitis, and pyelonephritis. On the basis of end users the market is segmented into hospitals and self-administered.

Regional Analysis of Middle East and Africa UTI Drugs Market:

UAE is the largest market of UTI drugs in Middle East and African UTI drugs market closely followed by Egypt. South Africa ranks high in the agendas of many Indian based pharmaceutical firms. The rest of African market is the fastest growing market of UTI drug since there are huge unmet medical needs.

The report about Middle East and Africa UTI Drugs Market by Market Research Future comprises extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value & volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of different markets segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mea-uti-drugs-market-2540

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Drug Discovery Informatics Market: Drivers, Restraints, Opportunities, and Threats (2020-2027)

Global drug discovery informatics markett size is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 1,680.6 million in 2017 and is projected to grow at a CAGR of 11.5% during the forecast period. Drug discovery and development is a highly intricate process requiring the generation of very large amounts of data and information. Large amounts of data are generated using a variety of innovative technologies, and the limiting step is accessing, searching and integrating this data. The current approaches to collect information from various sources have been dealt with in some cases where the data types are very least well-defined or largely homogeneous. However, the world is on the verge of a new age of drug discovery informatics, the methods and approaches in which are dealing with gathering information from data and knowledge from information are undergoing a paradigm shift. Mining and integration of domain-specific information such as chemical and genomic data will continue to develop in the near future.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7831

Drug discovery is a functional process in pharmaceutical and biotechnology companies. It involves different steps and procedures that depend on in-silico tools for reducing the complexity of a process. Some of the factors driving the market growth are a rising worldwide focus on drug discovery, growing need to control drug discovery and development costs, growth in R&D expenditure, and increasing burden of chronic diseases. For instance, according to the World Health Organization (WHO), in 2001, chronic diseases contributed around 60% of the 56.5 million total reported deaths across the world and approximately 46% of the global burden of disease, which is projected that, by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide. On the other hand, high pricing and setup cost of informatics software is anticipated to restrict the market growth during the forecast period.

Segmentation

The global drug discovery informatics market has been segmented into product, mode, service, end user, and region.

By product, the market has been segmented into discovery informatics and development informatics.

On the basis of mode, the market has been divided into in-house informatics and outsourced informatics.

By service, the market has been classified into sequencing and target data analysis, docking, molecular modeling, clinical trial data management, and others. The sequencing and target data analysis segment is expected to dominate the market over the forecast period due to rising application of informatics solutions in targeted analysis and a large amount of data generated during the drug discovery process.

Based on end user, the market has been categorized into pharmaceutical and biotechnology industries, contract research organizations (CROs), and others.

The global drug discovery informatics market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The drug discovery informatics market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European drug discovery informatics market has been segmented into Western Europe and Eastern Europe. The Western Europe drug discovery informatics market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The drug discovery informatics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The drug discovery informatics market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Few of the spearheads in the global drug discovery informatics market are Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Certara, L.P., Infosys Limited, Novo Informatics Pvt. Ltd., Collaborative Drug Discovery Inc., Selvita, Charles River Laboratories, Inc., International Business Machines Corporation, Jubilant Life Sciences Ltd., IO Informatics, Inc., GVK Biosciences Private Limited, and Dassault Systèmes.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/drug-discovery-informatics-market-7831

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Healthcare Information Systems Market Growth, Trends and Value Chain 2020-2027

The global healthcare information systems market size is expected to register a CAGR of 10.0% during the forecast period of 2018 to 2023.

Healthcare information technology offers solutions for security and data management of information related with healthcare. Currently, information technology has more effect on the cost quality and safety associated with healthcare. Some commonly used applications in the healthcare industry include electronic medical records, healthcare records and personal health records.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7325

Healthcare Information Systems Market Segmentation

The global healthcare information systems market is segmented based on type, components, deployment, end user, and region.

On the basis of type, the market is segmented into hospital information systems, pharmacy information systems, laboratory information systems, medical imaging information system, revenue cycle management. The hospital information systems segment is sub-segmented into electronic health record, electronic medical record, real-time healthcare, patient engagement solutions, population health management and others. The pharmacy information systems segment is sub-segmented into prescription management, automated dispensing systems, inventory management and others. The medical imaging information System is sub-segmented into radiology information systems, monitoring analysis software, picture archiving & communication systems and others. Based on components, the market is divided into two, i.e., Software and Hardware. Based on deployment, the market is divided into web-based, on premise and cloud-based. By end user, the market is divided into hospitals, diagnostics centre, academic and research institution, and others. In the current scope of the study, the above-mentioned segments are covered into four global regions, namely- the Americas, Europe, Asia Pacific and the Middle East & Africa.

Healthcare Information Systems Regional Market Summary

The Americas dominated the global market of healthcare information systems. Rising demand for high quality diagnostics system is the main reason behind the supremacy of the North America’s healthcare information system market. Furthermore, large-scale implementation and storage of electronic records in the healthcare system witnessed in the countries such as Canada and the U.S is supporting the expansion of this regional healthcare information system market.

In 2017, it was estimated that Europe stood second in the global healthcare information systems market. This can be attributed due to the presence of a well-developed healthcare infrastructure, increasing awareness for the condition and presence of developed economies within the region.

Asia Pacific was the fastest growing region for the global healthcare information systems market in 2017. Asia-Pacific has a huge market potential for Healthcare IT industry. India and China are some of the rapidly growing countries, followed by South Korea. Consequently, the government in these rapidly developing economies have taken various efforts to improve healthcare services and provide better infrastructure.

On the other hand, the Middle East and Africa held least share in the global healthcare information systems market. Presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. Most of the market share within this region is estimated to be held by the Middle East due to increasing government funding in the healthcare, and presence of developed economies like UAE, Kuwait, Dubai, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/healthcare-information-systems-market-7325

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Radiofrequency Ablation Devices Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

The global radiofrequency ablation devices market size is expected to register a CAGR of 11.2% during the forecast period of 2018 to 2023.

Radiofrequency ablation (RFA) uses thermal energy to achieve targeted tissue destruction. Within the GI tract, Radiofrequency ablation was primarily studied for the treatment of dysplastic Barrett’s esophagus (BE), and this continues to be one of the common applications. Indications for Radiofrequency ablation within the GI tract continue to progress. It has been used in the treatment of esophageal squamous cell dysplasia, cholangiocarcinoma, radiation proctopathy, gastric antral vascular ectasia (GAVE), and pancreatic neoplasia, among other conditions.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7634

Radiofrequency ablation devices use an electrosurgical generator connected to bipolar electrode arrays to deliver thermal energy to tissue. Electricity travels through tissue between alternating positive and negative poles along the electrode arrays of the radiofrequency ablation device in the radiofrequency range of 450 to 500 kHz.

Segmentation

The global radiofrequency ablation devices market is segmented on the basis of type, application, and region.

On the basis of the type, the global radiofrequency ablation devices market is segmented into Unipolar radiofrequency ablation and Bipolar radiofrequency ablation. By application, the global radiofrequency ablation devices market is categorized into Surgical Oncology, Cardiology and Cardiac Rhythm Management, Gynecology, Cosmetology, Pain Management

Key players

Some of the key players in the global radiofrequency ablation devices market are Boston scientific corporation, Medtronic Inc, Stryker, Cosman Medical, Inc., St. Jude Medical, Smith & Nephew, Johnson & Johnson (J&J) Services, LLC, Angiodynamics, RF Medical Co, Ltd, AtriCure, Inc., and others

Regional Market

The Americas dominates the global market for radiofrequency ablation devices owing a growing number of lung cancer cases like, Non-Small Cell Lung Cancer (NSCLC) which is the most common type of lung cancer, accounting for 80-85% of all lung cancer cases. It is generally a slow growing and spreading as compared to small cell lung cancer (SCLC). Small cell lung cancer used to account for 12-13% of lung cancers. However, there has been a shift from NSCLC to SCLC in recent years which has propelled the growth of the radiofrequency ablation devices market.

In 2017, it was estimated that Europe stood second in the global radiofrequency ablation devices market.

Asia-Pacific was the fastest growing region for the global radiofrequency ablation devices market in 2017. Factors such as increasing awareness of the cardiac disease, growing healthcare industries, and the development of various treatment methods for gynecology and cosmetology drives the market in this region.

On the other hand, the Middle East and Africa holds the least share in the global radiofrequency ablation devices market. The presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. A majority of the market share within this region is estimated to be held by the Middle East due to increasing government funding in the healthcare for healthcare, and presence of developed economies like UAE, Kuwait, Dubai, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/radiofrequency-ablation-devices-market-7634

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

New research report offers detailed research on developments in Q fever Market 2027

The Global Q fever market is expected to grow at CAGR of 7.83% to reach USD 6,249.68 thousand till 2023. Some of the protuberant drivers supporting the growth of the global Q fever market size are identified as growth in the prevalence of chronic diseases and the increasing number of patients suffering from various bacterial infections.

The rising prevalence of Q fever coupled with increasing Q fever hospitalization rates, rising worldwide cattle, sheep, and goat population, growth in the risk factors of Q fever, and globally growing geriatric population are expected to drive the global Q fever market in coming years.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5490

Segmentation

Global Q fever, by type, segmented into acute and chronic. Chronic is the leading segment, which is growing at the highest CAGR to reach USD 706.20 thousand by the end of 2023. Chronic Q fever is a life threating problem and causes damage to the heart, lungs, liver, brain, and could cause diabetes as well. The major share of the chronic segment is attributed to its high prevalence.

Based on diagnosis, Q fever market is segmented into serology tests and others. The serology tests account for major share with 8.32% CAGR during the forecast period. Under the serology test, Q fever is diagnosed through antibody blood tests, polymerase chain reaction (PCR) tests, immunoperoxidase staining, complement fixation, enzyme-linked immunosorbent assay (ELISA) tests, and other molecular tests.

The Q fever market, by treatment, is segmented into antibiotic and surgery. The antibiotics segment accounts for the second largest share in the market with 7.32% CAGR during the forecast period. Surgery is an important component of treatment if patients have extensive valvular damage or indications of heart failure.

On the basis of end user, the market is segmented into patients, hospitals and clinics, and others. The patient segment accounted for a considerable market share of 72.1% as of 2017.

Regional Analysis

The Asia-Pacific accounted for the largest market share of 44.5% as of 2017 and is projected to grow at the highest CAGR of 8.57% during the forecast period. The increasing prevalence of chronic diseases such as diabetes, cancer, and bacterial infection in developing countries is the major driver for market growth. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, which is expected to reach 642 million by 2040. It also stated that 98.4 million and 65.1 million diabetic population lived in China and India, respectively.

The Asia-Pacific is followed by Europe, which accounted for a major market share. The European market is expected to grow at a strong growth rate during the forecast period owing to the availability of advanced treatment facilities and healthcare expenditure along with growing pet adoption.

The Americas accounted for a significant share in the global Q fever market. It is attributed to the increasing adoption of pets, increasing preventive treatments, and care facilities for companion animals, rising technically advanced devices, and growing awareness regarding animal-transmitted diseases.

Key Players

The prominent players in the global Q fever market are Merck KGaA (Germany), Teva Pharmaceutical (Israel), Pfizer Inc. (US), Basilea Pharmaceutica Ltd (Switzerland), Sanofi S.A.(France), Melinta Therapeutics, Inc. (US), Bayer AG (Germany), Johnson & Johnson Services, Inc. (US), Yashica Pharmaceuticals (India), AtoxBio (US), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/q-fever-market-5490

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Hemostasis and Tissue Sealing Agents Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Hemostasis and Tissue Sealing Agents Market Scenario

Global hemostasis and tissue sealing agents market size is expected to grow significantly and is projected to grow at a CAGR of 8.6% over the forecast period. Hemostats, adhesives and sealants are useful aides to modern surgical procedures. Topical hemostats are utilized intraoperatively first and postoperatively to a reduce extent. These products can be utilized to diffuse raw surface bleeding, bone bleeding, oozing venous type bleeds, and needle-opening bleeding. There has been increasing demand for such products as it reduces complication during surgical procedures. Moreover, large number of surgical procedures across the globe are impacting the growth of the market positively. Surgical procedures are medical interventions involving an incision with instruments usually performed in an operating theatre and normally involving various medical devices such as catheters and tubes. For instance, according to the Center for Diseases Control and Prevention, approximately 46.5 million surgical procedures are performed every year in the U.S. Additionally, according to the NHS, surgery is the most important treatment offered by the NHS in secondary care within the UK. Furthermore, in 2015, NHS estimated that there were around 4.7 million surgical admissions in England, out of which 1.3 million procedures were for general surgery and around 1.2 million procedures were for trauma and orthopedics.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7559

These high surgical procedure numbers lead to rising need for hemostasis and tissue sealing agents which reduces the risk during surgical procedures. However, factors such as increasing advancement minimally invasive procedures, lack of reimbursement for these products is hampering the growth of the market.

Hemostasis and Tissue Sealing Agents Market Segmentation

The global hemostasis and tissue sealing agents market has been segmented into product, and end user.

By product, the market has been segmented into topical hemostats, and adhesive & tissue sealant. Furthermore, topical hemostats is divided into Active, mechanical (collagen based hemostats, cellulose based hemostats, gelatin based hemostats, polysaccharide based hemostats) Flowable. Adhesive & tissue sealant is further segmented into synthetic, natural, and adhesion barrier.

Further on the basis of end user the market is bifurcated into hospitals, ambulatory centers and others

The global Hemostasis and tissue sealing agents market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The diagnostics imaging workstations market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European Hemostasis and tissue sealing agents market has been segmented into Western Europe and Eastern Europe. The Western Europe diagnostics imaging workstations market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The diagnostics imaging workstations market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The diagnostics imaging services market in the Middle East & Africa has been segmented into the Middle East and Africa.

Hemostasis and Tissue Sealing Agents Market Key players

Johnson & Johnson, Cryolife, Inc., Baxter International, Inc, Ethicon LLC, Integra Lifesciences Corporation, Becton, Dickinson & Company, Cohera Medical, Inc., Pfizer, Inc, Medtronic plc, B. Braun Melsungen AG, MIL Laboratories Pvt. Ltd, Advanced Medical Solutions Group Plc

Hemostasis and Tissue Sealing Agents Regional Market Summary

Geographically, the Americas is anticipated to dominate the global hemostasis and tissue sealing agents market owing to the high clinical R&D budgets by both government as well as public and private organizations, presence of major manufacturers for the products, high number of surgical procedures and various others. Europe is expected to hold the second largest position in the global hemostasis and tissue sealing agents market. The Hemostasis and tissue sealing agents market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increased medical tourism for surgical procedures, increasing healthcare expenditure in developing countries and various others. The Middle East & Africa has the lowest share of the global hemostasis and tissue sealing agents market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hemostasis-tissue-sealing-agents-market-7559

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Small Animal Imaging Market Growth, Trends and Value Chain 2020-2027

Market Scenario

The global small animal imaging market is expected to gain prominence over the forecast period (2018–2027). It is estimated that the global small animal imaging market is expected to grow at a CAGR ~ 6.5 % during the forecast period of 2018–2027.

Small Animal Imaging Market Size is a process employed using imaging devices and reagents for monitoring the molecular or cellular process for biochemical, biological, diagnostic or therapeutic application in animals such as rats and mice for drug development and gene expression studies. Moreover, the small imaging systems are the cost-effective method for regular validation and commercialization of new drugs as it includes the whole body scan of the animals.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6175

The market growth is driven by the increasing demand for non-invasive small animal imaging techniques and technological advancements in the field of small animal imaging techniques. Furthermore, prominent market players are focused on continuous launches of product which is likely to contribute to the market growth. For instance, in September 2016, Aspect Imaging introduced M-series of compact MR imaging systems for pre-clinical research along with new integrated simultaneous PET-MRI systems.

However, stringent government regulations regarding animal usage in experiments and the high cost of devices may restrain the growth of global small animal imaging market.

Segmentation

The global small animal imaging market is segmented on the basis of the modality and reagents.

On the basis of the modality, the market is classified into optical imaging systems, nuclear imaging systems, micro-MRI systems, micro-ultrasound systems, micro-CT systems, photoacoustic imaging systems, and Magnetic Particle Imaging (MPI) systems. The optical imaging systems are further segmented into bioluminescence/ fluorescence imaging systems, standalone fluorescence imaging systems, and optical + X-Ray/optical + CT systems. The nuclear imaging systems are segmented into micro-Pet systems, micro-spect systems, and trimodality (spect/pet/CT) systems. The micro-pet system is further segmented into standalone pet systems, pet/CT system, and pet/MRI systems. The micro-spect system is further segmented into standalone spect systems, spect/CT system, and spect/MRI systems.

On the basis of reagent, the market is segmented as optical imaging reagents, nuclear imaging reagents, MRI contrast agents, ultrasound contrast agents, and CT contrast agents. The optical imaging reagents are further segmented as bioluminescent imaging reagents and fluorescent imaging reagents. The bioluminescent imaging reagents are further segmented into luciferins, pro-luciferins, coelenterazine, and other bioluminescent imaging reagents. The fluorescent imaging reagents are further segmented as green fluorescent proteins, red fluorescent proteins, infrared dyes, other fluorescent imaging reagents. The nuclear imaging reagents are segmented into pet tracers and spect probes. The pet tracers are further classified into fluorine-18-based small animal pet tracers, carbon-11-based small animal pet tracers, copper-64-based small animal pet tracers, and other spect probes. The spect probes are further segmented into technetium-99m-based small animal spect probes, iodine-131-based small animal spect probes, gallium-67-based small animal spect probes, thallium-201-based small animal spect probes, and other spect probes. The MRI contrast agents are segmented into gadolinium-based small animal contrast agents, iron-based small animal contrast agents, and manganese-based small animal contrast agents. The CT contrast agents are further segmented into iodine-based small animal CT contrast agents, barium-based small animal CT contrast agents, gold nanoparticles and gastrografin-based small animal CT contrast media.

Regional Analysis:

Geographically, the market has been segmented into America, Europe, Asia Pacific, and the Middle East & Africa. The Americas small animal imaging market is further segmented into North America, and South America. North America is further classified as U.S. and Canada.

The Europe small animal imaging market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, U.K., Italy, Spain, and the Rest of Western Europe.

The Asia Pacific small animal imaging market is segmented into Japan, China, India, Republic of Korea, Australia, and the Rest of Asia Pacific.

The Middle East & Africa small animal imaging market is segmented into the Middle East and Africa.

Get Full Report at https://www.marketresearchfuture.com/reports/small-animal-imaging-market-6175

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com